These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Future prospects in developing of dengue vaccines].
    Author: Valero N, Levy A.
    Journal: Invest Clin; 2008 Jun; 49(2):135-8. PubMed ID: 18717261.
    Abstract:
    Dengue is a viral, febrile and acute disease that causes more morbility than any other infection for Arbovirus. It becomes necessary to implement a safe and effective vaccine that will contribute to the eradication of this disease, especially in endemic areas with very low socio-economic conditions. The only option that exists at the present to control the transmission of the disease is through vector control. So far, there are no effective antiviral drugs for flavivirus such as dengue. Candidates for vaccines for this disease, who are currently in advanced stages of development, are live attenuated vaccine, live attenuated chimerics, inactivated virus, subunits and DNA, in order to mimic the natural infection. The requirements for an ideal vaccine capable of protecting the population at risk should be: free reactogenicity, one which induces protection against all four serotypes of the virus (tetravalent), that offers effective prolonged protection; it also should be highly immunogenic, with few side effects, easy administration, available at low cost and should be administered in one dose, both in adults and in children. Meanwhile, efforts to try to give immunoprophylaxis for this disease continue, in order to design an ideal vaccine allowing the eradication of the disease and the reduction in the number of cases which affects our people every day.
    [Abstract] [Full Text] [Related] [New Search]